

ASX:NRT

NASDAQ:NVGN

Novogen Ltd
(Company)

ABN 37 063 259 754

Capital Structure

Ordinary Shares on
issue:

185 M

Board of Directors

Dr Graham Kelly
Chairman &
Executive Director

Steve Coffey
Non Executive Director

John O'Connor
Non Executive Director

Prof Peter Gunning
Non Executive Director

ASX RELEASE

20 November 2014

MR IAIN ROSS RESIGNS AS NON- EXECUTIVE DIRECTOR

Sydney, AUSTRALIA, 20 November 2014: Novogen today announced that Non-Executive Director, Mr Iain Ross has resigned as an independent Director of Novogen with immediate effect as a result of an unforeseen conflict of interest.

Novogen CEO and Executive Chairman, Dr Graham Kelly, said, "It is unfortunate that this unforeseen conflict of interest has arisen as Iain brought a considerable depth of experience to the Board. It also means that I will continue in the dual roles of CEO and Executive Chairman to oversee the transformation of the Company into a clinical-stage company, bringing our US-subsiary CanTx Inc into a fully-functioning clinical-stage company, and continuing with our dual ASX and NASDAQ listings."

About Novogen Limited

Novogen is a public, Australian drug-development company whose shares trade on both the Australian Securities Exchange ('NRT') and NASDAQ ('NVGN'). The Novogen Group includes a New Haven CT – based joint venture company, CanTx Inc., with Yale University.

Novogen has two main drug technology platforms: super-benzopyrans (SBPs) and anti-tropomyosins (ATMs). SBP compounds have been created to kill the full range of cells within a tumor, but particularly the cancer stem cells. The ATM compounds target the microfilament component of the cancer cell and when used in conjunction with standard anti-microtubular drugs, result in comprehensive and fatal destruction of the cancer cell's cytoskeleton. Ovarian cancer, colorectal cancer, malignant ascites, prostate cancer, neural cancers (glioblastoma, neuroblastoma in children) and melanoma are the key clinical indications being pursued, with the ultimate objective of employing both technologies as a unified approach to first-line therapy.

Further information is available on our websites www.novogen.com

Further information

Dr. Graham Kelly
Executive Chairman & CEO Novogen Group

Graham.Kelly@novogen.com

+61 (0) 2 9472 4100